NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/16/2026
Back to search
Official data from USPTO
ADIPOPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
06/16/2026
Trademark type
Combined
Nice classes
5, 42
Filing date
04/01/2025
Registration date
06/16/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/16/2026
Last transaction
06/16/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
34
Owner location
FR
Examiner
HUDSON, TAMARA BREE
Law office
L40
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the wording "ADIPOPHARMA" in stylized font wherein the lettering "ADIPO" is in blue and "PHARMA" is in pink; to the left of the wording is a stylized cloud-like formation which appears from left to right in the colors white with grey shading, blue with dark blue shading, white with grey shading, pink with dark pink shading, blue with dark blue shading, and white with grey shading; partially enclosing the right side of the formation is the orange outline of an incomplete circle.
Holders and representatives
Holders
AdipoPharma
Representatives
Pina Campagna Carter, DeLuca, & Farrell, LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary preparations for treating and preventing diabetesinsulin resistancepancreaticliver and kidney diseasescardiovascular diseasesfibrosismetabolic disorders; medications for human medicine for treating and preventing diabetesinsulin resistancepancreaticliver and kidney diseasescardiovascular diseasesfibrosismetabolic disorders; chemical preparations for medical use for treating and preventing diabetesinsulin resistancepancreaticliver and kidney diseasescardiovascular diseasesfibrosismetabolic disorders; chemical preparations for pharmaceutical use for treating and preventing diabetesinsulin resistancepancreaticliver and kidney diseasescardiovascular diseasesfibrosismetabolic disorders; diagnostic preparations for medical use; cultures of microorganisms for medical use; stem cells for medical use; sanitary preparations for medical purposes; foodstuffs and dietetic food and beverages adapted for medical or veterinary use
Class 42
Scientific and technological servicesresearch and design relating to drugspharmaceuticalsmedicine; research and development services in the field of pharmacy and in particular medicines; research and development of new products for third parties; biological research; bacteriological research; chemical research; cosmetic science research; technical research in the field of new product development; scientific laboratory services; chemical analysis; material testing; technical project studies namelyconducting of feasibility studies in the field of new technologies; surveying being engineering servicesengineering
Publications
History of USPTO decisions and trademark events.
22 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/16/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/28/2026
PUBO
PUBLISHED FOR OPPOSITION
04/28/2026
GPNX
NOTIFICATION PROCESSED BY IB
04/23/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/22/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/16/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/08/2026
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/08/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/27/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/25/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/25/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/25/2026
RFNT
REFUSAL PROCESSED BY IB
11/15/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/28/2025
RFRR
REFUSAL PROCESSED BY MPU
10/28/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/11/2025
CNRT
NON-FINAL ACTION WRITTEN
09/10/2025
DOCK
ASSIGNED TO EXAMINER
08/28/2025
MAFR
APPLICATION FILING RECEIPT MAILED
06/06/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/06/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/05/2025
Continuous trademark protection
Get notified about every new filing that threatens ADIPOPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.